Diamyd Medical
在场
Diamyd Medical 是一家在股票代码 DMN (SE) 下上市的公司。
高管
查看带有其 14 名主要高管的组织结构图
Diamyd Medical 搜索最多的简介
高管在Diamyd Medical变化
- Anders Essen-Möller 曾任 Board Member, 现升职为 Chairman of the Board (新闻发布的2023十月2号).
创建提醒
跟踪 Diamyd Medical 的高管变动
生物技术
Diamyd Medical 拥有 2,275 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
- Nurix Therapeutics 刚刚宣布为 175 筹款数百万美元。 (公布2024四月13号).
生物技术 行业的其他推荐联系人
消息
Diamyd Medical 的最新新闻稿
- Recruitment milestone reached in Diamyd® Phase 3 trial
- Diamyd Medical's main Shareholders announce their subscription commitments in the ongoing rights issue
- Diamyd Medical led ASSET innovation partnership organizes a workshop on the future treatment of Type 1 Diabetes
- Publication in Diabetologia highlights AI's potential for Type 1 Diabetes screening
- The Board of Directors in Diamyd Medical have resolved on a rights issue of approximately SEK 114 million
- Diamyd Medical to present new genetic data at the ASIT summit in Boston, MA
- Diamyd Medical receives U.S. FDA Fast Track designation for Diamyd®
- Quarterly Report I 23/24
- In-depth analysis of Diamyd® Phase II trial further supports value of preserved insulin secretion
- Diamyd Medical gains market research findings to guide U.S. commercial strategy
- View more press releases Close
关于 Diamyd Medical 的社交媒体
保持联系
通过电子邮件联系联系该企业高管，包括 Ulf Hannelius 
